Technology

PEP-Therapy owns IP rights for the exploitation of an innovative technology called CP&IP (Cell Penetrating & Interfering Peptides). These innovative peptides penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.

 

Two major innovations have been combined in a single bi-functional peptide to target efficiently and accurately key cellular mechanisms involved in pathologies:

  • Optimized Cell Penetrating Peptides (CPP), as a "shuttle" to deliver drugs pharmaceutically active peptides into the cell and also into specific organelles;

  • Short Interfering peptides specifically designed to target relevant protein/protein interactions, thus blocking key mechanisms of diseases, with no effect on other physiological functions of the two proteins.

Technology

The combination of both functionalities has led to the development of a unique technology with intracellular uptake and targeting, good in vivo stability and safety profile, and the versatility to address hard-to-reach intracellular targets, with high specificity in multiple pathologies.

Based on the proof-of-concept on lead product, PEP-Therapy will reinforce its product pipeline based on the CP&IP technology.

Our CP&IP technology can be applied to other new peptide projects for in-licensing.

© PEP-Therapy 2014-2020